1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,794 | 2,956 | 10:05 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.06. | GENFLEET-B GFH375 Monotherapy Data in Cholangiocarcinoma Show Preliminary Efficacy | 2 | AASTOCKS | ||
| 02.06. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375 MONOTHERAPY DATA PRESENTED AT 2026 ASCO ORAL SESSION: WORLD'S FIRST DEDICATED DATA OF A RAS INHIBITOR ... | 1 | HKEx | ||
| GENFLEET THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 01.06. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT PRELIMINARY PHASE I DATA OF GFS202A FOR CACHEXIA PRESENTED IN POSTER SESSION OF 2026 ASCO ANNUAL MEETING, FEATURING ... | 1 | HKEx | ||
| 11.05. | GENFLEET-B (02595): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 11, 2026 | 1 | HKEx | ||
| 28.04. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT STATEMENT ON THE PROPRIETARY INTELLECTUAL PROPERTY STATUS OF GFH276, A PAN RAS (ON) INHIBITOR | 1 | HKEx | ||
| 17.04. | GENFLEET-B (02595): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, 11 MAY 2026 | 1 | HKEx | ||
| 17.04. | GENFLEET-B (02595): NOTICE OF THE 2025 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 17.04. | GENFLEET-B (02595): CIRCULAR OF THE 2025 ANNUAL GENERAL MEETING | - | HKEx | ||
| 17.04. | GENFLEET-B (02595): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 09.04. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375 GRANTED WITH SECOND BREAKTHROUGH THERAPY DESIGNATION, AS THE FIRST KRAS G12D INHIBITOR MONOTHERAPY INCLUDED ... | 1 | HKEx | ||
| 25.03. | GENFLEET-B (02595): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 2 | HKEx | ||
| 25.03. | GENFLEET-B (02595): TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 25.03. | GENFLEET-B (02595): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | 3 | HKEx | ||
| 25.03. | GENFLEET-B (02595): (1) ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025; (2) CHANGE OF THE JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE ... | 1 | HKEx | ||
| 20.03. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT PRECLINICAL RESEARCH DATA OF THREE LARGE- AND SMALL-MOLECULE TARGETED THERAPIES RELEVANT TO RAS PATHWAY TO ... | 1 | HKEx | ||
| 11.03. | GENFLEET-B (02595): DATE OF BOARD MEETING | 1 | HKEx | ||
| 09.03. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT INCLUSION INTO THE STOCK LIST OF THE STOCK CONNECT PROGRAM (SHANGHAI-HONG KONG STOCK CONNECT AND SHENZHEN-HONG ... | 1 | HKEx | ||
| 02.03. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375 GRANTED WITH FIRST BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR A KRAS G12D INHIBITOR TREATING NON-SMALL ... | 1 | HKEx | ||
| 13.02. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT INCLUSION AS A CONSTITUENT OF HANG SENG INDEX SERIES AND MSCI INDEX | 4 | HKEx | ||
| 09.02. | GENFLEET-B (02595): ARTICLES OF ASSOCIATION | 1 | HKEx |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 132,68 | -0,01 % | Apogee Therapeutics vor Übernahme: sharedealsPlus-Tipp wird zum Multibagger | Nachdem wir die Aktie von Apogee Therapeutics bereits im vergangenen Jahr zu Preisen von rund 40 US$ als heißen Buyout-Kandidaten vorgestellt hatten und sich ihr Kurs zwischenzeitlich mehr als verdoppeln... ► Artikel lesen | |
| ABSCI | 10,070 | -0,05 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,250 | 0,00 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| VERA THERAPEUTICS | 39,510 | 0,00 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen | |
| IMMUNOVANT | 38,220 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,540 | +0,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress | - JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145... ► Artikel lesen | |
| TANGO THERAPEUTICS | 29,120 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Appoints Robert Azelby to Board of Directors | BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 59,13 | 0,00 % | Kiniksa Pharmaceuticals Aktie markiert Rekordhoch bei 59,89 USD | ||
| TARSUS PHARMACEUTICALS | 67,11 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 308,81 | -0,04 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| BEAM THERAPEUTICS | 33,900 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| CG ONCOLOGY | 68,79 | +0,10 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 47,800 | +0,06 % | Hedge Fund and Insider Trading News: John Paulson, Warren Buffett, Ray Dalio, Brevan Howard, Rokos Capital Management, Noble Corp PLC (NE), Enliven Therapeutics Inc (ELVN), and More | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 20,010 | +0,05 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering | ZUG, Switzerland, June 23, 2026 - MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and... ► Artikel lesen | |
| NURIX THERAPEUTICS | 19,300 | 0,00 % | Nurix, BioNxt Solutions, Zealand Pharma - Neue Therapien sorgen für Fantasie | Der Biotech-Sektor erlebt derzeit eine Phase enormer Dynamik. Besonders Therapien gegen Adipositas, Diabetes, Autoimmunerkrankungen und neurologische Leiden zählen zu den größten Wachstumsmärkten im... ► Artikel lesen |
GENFLEET THERAPEUTICS SHANGHAI INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,08 % bei einem Aktienkurs von 3,140 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLEET THERAPEUTICS SHANGHAI INC finden Sie auf Wallstreet Online.